Methods for one-dose intradermal delivery for non-live trivalent influenza vaccine
The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation.
1. A method for vaccinating an individual selected from a human population of at least 18 years of age, the method comprising administering intradermally to said individual a single dose of a trivalent, split or subunit influenza vaccine antigen preparation, using a short needle device wherein the vaccine is provided in a dose volume of between about 0.05 and about 0.2 ml and wherein the vaccine induces a protective immune response in the human population of at least 18 years of age, wherein said protective immune response meets at least one criterion chosen from the group of:
(1) a protection rate of >70% in adults of 18-60 years of age or of >60% in elderly people of above 60 years of age;
(2) a seroconversion rate of >40% in adults of 18-60 years of age or of >30% in elderly people of above 60 years of age; or
(3) a conversion factor of >2.5 HI titres in adults of 18-60 years of age or of >2.0 HI titres in elderly people of above 60 years of age, for each influenza strain.
2. The method according to claim 1 , wherein the influenza antigen is egg-derived.
3. The method according claim 1 , wherein the vaccine further comprises an adjuvant comprising a combination of cholesterol, a saponin and an LPS derivative.
4. The method according to claim 1 , wherein said influenza vaccine antigen preparation is obtained by a process comprising: (i) harvesting virus-containing material from a culture; (ii) clarifying the harvested material to remove non-virus material; (iii) concentrating the harvested virus; (iv) separating whole virus from non-virus material; (v) splitting the whole virus using a suitable splitting agent in a density gradient centrifugation step; and (vi) filtering the product of step (v) to remove undesired materials.
5. The method according to claim 1 , wherein the vaccine antigen preparation is a trivalent, split influenza vaccine antigen preparation.
6. The method according to claim 1 , wherein the vaccine antigen preparation is a trivalent, subunit influenza vaccine antigen preparation.
7. The method according to claim 1 , wherein said protective immune response meets at least two criteria chosen from the group of: (1) a protection rate of >70% in adults of 18-60 years of age or of >60% in elderly people of above 60 years of age; (2) a seroconversion rate of >40% in adults of 18-60 years of age or of >30% in elderly people of above 60 years of age; or (3) a conversion factor of >2.5 HI titres in adults of 18-60 years of age or of >2.0 HI titres in elderly people of above 60 years of age, for each influenza strain.
8. The method according to claim 7 , wherein the influenza antigen is egg-derived.
9. The method according to claim 7 , wherein the vaccine is provided in a dose volume of between about 0.1 and about 0.2 ml.
10. The method according to claim 7 , wherein the vaccine further comprises an adjuvant comprising a combination of cholesterol, a saponin and an LPS derivative.
11. The method according to claim 7 , wherein the vaccine antigen preparation is a trivalent, split influenza vaccine antigen preparation.
12. The method according to claim 7 , wherein the vaccine antigen preparation is a trivalent, subunit influenza vaccine antigen preparation.
13. The method according to claim 7 , wherein said influenza vaccine antigen preparation is obtained by a process comprising: (i) harvesting virus-containing material from a culture; (ii) clarifying the harvested material to remove non-virus material; (iii) concentrating the harvested virus; (iv) separating whole virus from non-virus material, (v) splitting the whole virus using a suitable splitting agent in a density gradient centrifugation step; and (vi) filtering the product of step (v) to remove undesired materials.
14. The method according to claim 1 , wherein said protective immune response meets all three criteria chosen from the group of (1) a protection rate of >70% in adults of 18-60 years of age or of >60% in elderly people of above 60 years of age; (2) a seroconversion rate of >40% in adults of 18-60 years of age or of >30% in elderly people of above 60 years of age; and (3) a conversion factor of >2.5 HI titres in adults of 18-60 years of age or of >2.0 HI titres in elderly people of above 60 years of age, for each influenza strain.
15. The method according to claim 14 , wherein the influenza antigen is egg-derived.
16. The method according to claim 14 , wherein the vaccine is provided in a dose volume of between about 0.1 and about 0.2 ml.
17. The method according to claim 14 , wherein the vaccine antigen preparation is a trivalent, split influenza vaccine antigen preparation.
18. The method according to claim 14 , wherein the vaccine antigen preparation is a trivalent, subunit influenza vaccine antigen preparation.
19. The method according claim 14 , wherein the vaccine further comprises an adjuvant comprising a combination of cholesterol, a saponin and an LPS derivative.
20. The method according to claim 14 , wherein said influenza vaccine antigen preparation is obtained by a process comprising, (i) harvesting virus-containing material from a culture; (ii) clarifying the harvested material to remove non-viral material; (iii) concentrating the harvested virus; (iv) separating whole virus from non-virus material; (v) splitting the whole virus using a suitable splitting agent in a density gradient centrifugation step; and (vi) filtering the product of step (v) to remove undesired materials.